The Food and Drug Administration on Thursday approved COVID-19 vaccines for the 2026-27 season for people at higher risk of severe illness, including everyone 65 and older and younger people with certain underlying health conditions.

The FDA approved Moderna’s vaccine for people ages 6 months and older, Pfizer’s for those ages 5 and older, and Sanofi’s for people ages 12 and older. The agency also approved a lower-dose Moderna vaccine, mNEXSPIKE, for people ages 12 and up.

Recommended Stories

FDA approves new COVID-19 vaccine

Moderna requests authorization for COVID-19 vaccine for children under 6

Officials investigating whether Moderna vaccine linked to increased risk of heart inflammation